VYNE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.5 USD | +1.21% |
|
+11.11% | +7.30% |
| 04-04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
| 02-29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 265.2 | 54.59 | 8.705 | 32.52 | 35.25 | - | - |
| Enterprise Value (EV) 1 | 265.2 | 54.59 | 8.705 | 32.52 | 35.25 | 35.25 | 35.25 |
| P/E ratio | -0.8 x | -0.72 x | -0.37 x | -0.84 x | -2.5 x | -2.6 x | -2.38 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.6 x | 3.7 x | 18.3 x | 76.7 x | 88.1 x | 141 x | 141 x |
| EV / Revenue | 12.6 x | 3.7 x | 18.3 x | 76.7 x | 88.1 x | 141 x | 141 x |
| EV / EBITDA | - | - | - | -1.11 x | -1.01 x | -0.86 x | -0.76 x |
| EV / FCF | -1,933,366 x | -968,444 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,332 | 2,973 | 3,224 | 13,957 | 14,099 | - | - |
| Reference price 2 | 113.8 | 18.36 | 2.700 | 2.330 | 2.500 | 2.500 | 2.500 |
| Announcement Date | 21-03-04 | 22-03-17 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.443 | 20.99 | 14.76 | 0.477 | 0.424 | 0.4 | 0.25 | 0.25 |
| EBITDA 1 | - | - | - | - | -29.26 | -35 | -40.9 | -46.4 |
| EBIT 1 | -95.87 | -252.5 | -68.03 | -34.3 | -29.26 | -35 | -47.75 | -53 |
| Operating Margin | -21,641.76% | -1,203% | -461.08% | -7,189.73% | -6,900.47% | -8,750% | -19,100% | -21,200% |
| Earnings before Tax (EBT) 1 | -95.35 | -255.8 | -73.78 | -33.93 | -27.87 | -33.5 | -40.7 | -46.2 |
| Net income 1 | -95.18 | -255.6 | -73.33 | -23.21 | -28.45 | -33.5 | -40.7 | -46.2 |
| Net margin | -21,484.88% | -1,217.4% | -496.98% | -4,865.83% | -6,710.38% | -8,375% | -16,280% | -18,480% |
| EPS 2 | - | -141.8 | -25.56 | -7.280 | -2.780 | -1.000 | -0.9600 | -1.050 |
| Free Cash Flow | -74.45 | -137.2 | -56.37 | - | - | - | - | - |
| FCF margin | -16,806.32% | -653.53% | -382.02% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-12 | 21-03-04 | 22-03-17 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.086 | 2.292 | 0.178 | 0.126 | 0.167 | 0.006 | 0.099 | 0.135 | 0.114 | 0.076 | 0.1 | 0.11 | 0.11 | 0.13 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | -8.1 | -8.5 | -8.9 | -9.5 |
| EBIT | -17.78 | -12.04 | -8.691 | -8.287 | -9.333 | -7.984 | -5.875 | -10.32 | - | - | - | - | - | - |
| Operating Margin | -435.05% | -525.48% | -4,882.58% | -6,576.98% | -5,588.62% | -133,066.67% | -5,934.34% | -7,642.96% | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.28 | -12.02 | -8.694 | -8.235 | -9.255 | -7.748 | -5.612 | -10.04 | -6.071 | -6.152 | -7.8 | -8.2 | -8.5 | -9.1 |
| Net income 1 | -21.28 | -11.57 | 4.67 | -8.476 | -9.459 | -9.945 | -5.622 | -10.06 | -6.584 | -6.188 | -7.791 | -8.2 | -8.5 | -9.1 |
| Net margin | -520.93% | -504.8% | 2,623.6% | -6,726.98% | -5,664.07% | -165,750% | -5,678.79% | -7,450.37% | -5,775.44% | -8,142.11% | -7,791% | -7,454.55% | -7,727.27% | -7,000% |
| EPS 2 | -7.380 | -3.960 | 1.440 | -2.700 | -2.880 | -3.330 | -1.740 | -3.090 | -2.010 | -0.2000 | -0.2400 | -0.2500 | -0.2500 | -0.2700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-10 | 22-03-17 | 22-05-12 | 22-08-12 | 22-11-10 | 23-03-09 | 23-05-11 | 23-08-14 | 23-11-13 | 24-02-29 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -74.5 | -137 | -56.4 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 1.06 | 0.11 | - | - | - | - | - | - |
| Capex / Sales | 238.83% | 0.54% | - | - | - | - | - | - |
| Announcement Date | 20-03-12 | 21-03-04 | 22-03-17 | 23-03-09 | 24-02-29 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.5
USD
Average target price
5.583
USD
Spread / Average Target
+123.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.30% | 35.25M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- VYNE Stock
- Financials VYNE Therapeutics Inc.
